Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pregabalin as adjunctive therapy for partial seizures.

Martin J Brodie1

  • 1Epilepsy Unit, University of Glasgow, Glasgow G11 6NT, Scotland, UK. J.Brodie@clinmed.gla.ac.uk

Epilepsia
|August 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do the third-generation antiseizure medications provide the "magic bullet" for drug-resistant epilepsy? Focus on cenobamate.

Epilepsia·2025
Same author

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy.

Epilepsia open·2025
Same author

The impact of COVID-19 on people with epilepsy: Global results from the coronavirus and epilepsy study.

Epilepsia open·2024
Same author

Editorial: Epidemiology of epilepsy and seizures.

Frontiers in epidemiology·2024
Same author

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial.

JAMA neurology·2023
Same author

Should substitution monotherapy or combination therapy be used after failure of the first antiseizure medication? Observations from a 30-year cohort study.

Epilepsia·2023

Pregabalin effectively reduces seizure frequency in patients with partial epilepsy when used as adjunctive therapy. This adjunctive treatment demonstrated significant efficacy and a favorable safety profile in clinical trials.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Epilepsy affects millions globally, with many patients experiencing refractory partial seizures.
  • Current adjunctive therapies for epilepsy have limitations in efficacy and tolerability.

Purpose of the Study:

  • To evaluate the efficacy and safety of pregabalin as adjunctive therapy for partial-onset seizures.
  • To establish optimal dosing and assess the dose-response relationship of pregabalin.

Main Methods:

  • Three randomized, double-blind, placebo-controlled trials involving 1,052 highly refractory epilepsy patients.
  • Patients received fixed doses of pregabalin (150-600 mg/day) or placebo for 12 weeks.
  • Efficacy assessed by seizure frequency reduction and responder rates; safety evaluated through adverse event monitoring.

Related Experiment Videos

Main Results:

  • Pregabalin significantly reduced seizure frequency compared to placebo across multiple doses (150-600 mg/day).
  • Responder rates approached 50% at 600 mg/day, indicating substantial seizure control.
  • Efficacy was observed as early as week one, with CNS-related adverse events being mild and generally self-limiting.

Conclusions:

  • Pregabalin is a highly effective adjunctive therapy for partial-onset seizures with or without secondary generalization.
  • The drug exhibits a clear dose-response relationship and a favorable safety profile in refractory epilepsy patients.
  • Dosing regimens (twice or thrice daily) did not significantly impact efficacy.